Literature DB >> 4306126

Treatment of breast cancer with medroxyprogesterone acetate.

F M Muggia, P A Cassieth, M Ochoa, F A Flatow, A Gellhorn, G A Hyman.   

Abstract

Entities:  

Keywords:  Biology; Breast Cancer; Cancer; Clinical Research; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--side effects; Contraceptive Agents, Progestin--therapeutic use; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Contraceptive Agents--therapeutic use; Depo-provera; Diseases; Endocrine System; Estrogens--administraction and dosage; Estrogens--therapeutic use; Family Planning; Hormones; Medroxyprogesterone Acetate--administraction and dosage; Medroxyprogesterone Acetate--side effects; Medroxyprogesterone Acetate--therapeutic use; Men; Menopause; Neoplasms; Oral Contraceptives, Combined; Physiology; Reproduction; Research Methodology; Women

Mesh：

Substances：

Year:  1968        PMID： 4306126     DOI： 10.7326/0003-4819-68-2-328

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  9 in total

1.  High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Authors:  M De Lena; C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 2.  Current status of the management of patients with endocrine-sensitive tumors. I. Introduction and carcinoma of the breast.

Authors:  L G Crowley
Journal:  Calif Med       Date:  1969-01

3.  Hormonal management of breast cancer.

Authors:  F M Muggia
Journal:  Br Med J       Date:  1969-07-19

Review 4.  Exogenous reproductive hormone use in breast cancer survivors and previvors.

Authors:  Ines Vaz-Luis; Ann H Partridge
Journal:  Nat Rev Clin Oncol       Date:  2018-01-23       Impact factor: 66.675

5.  Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer.

Authors:  G N Hortobagyi; A U Buzdar; D Frye; H Y Yap; V Hug; K Pinnamaneni; G Fraschini; H C Halvorson; G R Blumenschein
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

6.  Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.

Authors:  M Salimtschik; H T Mouridsen; J Loeber; E Johansson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 7.  Long acting contraceptives. Present status.

Authors:  G Benagiano; F M Primiero
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

Review 8.  Androgen Receptor: A Complex Therapeutic Target for Breast Cancer.

Authors:  Ramesh Narayanan; James T Dalton
Journal:  Cancers (Basel)       Date:  2016-12-02       Impact factor: 6.639

Review 9.  The Androgen Receptor in Breast Cancer.

Authors:  Pia Giovannelli; Marzia Di Donato; Giovanni Galasso; Erika Di Zazzo; Antonio Bilancio; Antimo Migliaccio
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-28       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.